ISLB President Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai, New York, NY, USA.

The trajectory Dr. María José Serrano is based on oncological research and mainly focused on the area of liquid biopsy, with more than 23 years of an experience in this type of analyses. During her career she has made different stays in Spain (Bilbao, Pamplona, Barcelona) and abroad (Tromso Norway). Currently, she is Principal investigator of the Liquid Biopsy and Cancer Interception group (LiqBiopCI) at GENyO center and in the Oncology department in the Uni Hospital Virgen de las Nieves.

Umberto Malapelle is the Chair of Predictive Molecular Pathology Laboratory, of the University of Naples Federico II.He was appointed in December 2015 Assistant Professor in Anatomic Pathology in School of Medicine, University of Naples Federico II. Currently his main research interest is in the field of genomic biomarkers validation and testing for predictive information in the field of lung cancer, metastatic colorectal cancer, melanoma and gastrointestinal stromal tumor.

University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA David R. Gandara, MD is a Professor of Medicine at the University of California at Davis (UCD) School of Medicine, is the Senior Advisor to the Director, and Director of the Thoracic Oncology Program at UC Davis Comprehensive Cancer Center (UCDCCC). He is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology.

ELOISA JANTUS LEWINTRE is Associate Professor at the Department of Biotechnology, Polytechnic University of Valencia, Head of the Molecular Oncology Laboratory at General University Hospital of Valencia Research Foundation, Co-PI in the Respiratory Tract Tumors Program of the Spanish Oncology Network of Biomedical Research (CIBERONC) and member of the Board of Directors of ISLB. She authored more than 80 articles in the oncology area (H-index: 20).

Charles completed his MDPhD training in 1999 at the Imperial Cancer Research Fund Laboratories and Cancer Research UK clinician scientist/medical oncology training in 2008. Charles is a senior group leader of the Cancer Evolution and Genome Instability Laboratory at the Francis Crick Institute  and combines his research with clinical duties at UCLH, as a thoracic oncologist, focussed on how tumours evolve over space and time. Charles research branched evolutionary histories of solid tumours.

Dr Catherine Alix-Panabières received her PhD-degree in Strasbourg (1998). She is associate professor - director of the LCCRH at the UMC Montpellier. These last 22 years, she put huge efforts on the analysis of CTCs in cancer patients. She coined for the first time ‘Liquid Biopsy’ in 2010 with Klaus Pantel. She authored >110 scientific publications and is the inventor of 3 patents in the liquid biopsy field. She is involved in many national and international liquid biopsy-based clinical trials.

IKERBASQUE Prof at CIC bioGUNE (Spain). Head of EXOSOMES lab and METABOLOMICS platform. Biochemistry and cellular biologist with wide experience in performing omics-based analyses. Since 2006, study EXOSOMES as disease biomarker and a tool for therapeutic applications. He has characterized EVs secreted by in vivo and in vitro experimental models of several diseases, and from bodily fluids, >50 publications related with extracellular vesicles. GEIVEX co-founder and part of the board of ISEV.

Associate Professor, University of Duisburg Essen, Germany

Dr Aceto is Prof of Molecular Oncology at the ETH Zurich. Previously, he was an Assistant Prof of Oncology at the Univ of Basel, Switzerland, and prior to that, postdoctoral fellow at Harvard Medical School and MGH Cancer Center Boston, USA. Recent discoveries of the Aceto lab include important insights into the metastatic process, namely investigations of the biology and vulnerabilities of CTC clusters, some of which already translated in clinical trials for patients with metastatic breast canc

I did my PhD in the laboratory of Dr. Amparo Cano in Madrid in 2003. I joined Dr. Lyden’s laboratory at Weill Cornell Medicine, New York in 2008, my work there defined that tumor- secreted exosomes in pre-metastatic niche formation. I joined CNIO in 2015 as the group leader of the laboratory of Microenvironment and Metastasis. My current research goals are focused on understanding the role of tumor-secreted extracellular vesicles during metastasis and the use of extracellular vesicles in LB

Consultant Medical Oncologist Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Australia

Dr. Sholl is a pathologist at Brigham and Women’s Hospital (BWH) in Boston and Associate Professor of Pathology at Harvard Medical School. She completed her medical schooling at Stanford University School of Medicine, followed by internal medicine internship at the Hospital of University of Pennsylvania, anatomic pathology residency at BWH, and the molecular genetics pathology fellowship at Harvard.

University of California Davis Comprehensive Cancer Center, Sacramento, CA - Mount Sinai Tisch Cancer Institute, New York, NY

Miguel Ángel Molina-Vila holds a PhD in Biochemistry and Molecular Biology. During a 25 year experience in translational research, in hospitals such as MD Anderson Cancer Center or Vall d’Hebron Hospital, he has co-authored of more than 90 peer reviewed publications in cancer and medical journals. A member of the Scientific Committee of the Spanish Lung Cancer Group (SLCG), he is currently the Technical Director of the Laboratory of Oncology at the Quiron Dexeus University Hospital, in Barcelona

Prof Di Nicolantonio holds a joint appointment as Director of the Laboratory of Cancer Epigenetics at the Candiolo Cancer Institute in Italy and as Associate Professor in biochemistry at the University of Torino. Her research focuses on the molecular mechanisms underlying cancer cells' response to antineoplastic drugs using a combination of preclinical models, and patient tissue and liquid biopsies.

Medical Oncology, Princess Margaret, Toronto, ON, Canada

Dept of Medicine, Division of Hem/Onc, University of Pennsylvania, PA, USA

Memorial Sloan-Kettering Cancer Center, New York, NY, USA

University of Melbourne, Australia

University of South California USC, USA

Chiara Cremolini is an Associate Professor in Medical Oncology at the University of Pisa in Italy. She actively contributes to clinical trials by Gruppo Oncologico del Nord Ovest (GONO), an Italian Foundation involved in the design and conduction of clinical and translational studies in the field of several solid malignancies, serving as Scientific Secretary from 2015 to 2021 and as President since April 2021, and participates to the activity of the ESMO Faculty Member for the GI tumors.

IRCCS, Humanitas Research Hospital, Milan, Italy

The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK

Princess Margaret, Ontario, Canada Dr. Lillian Siu is a senior medical oncologist at Princess Margaret Cancer Centre, and a Professor of Medicine at the University of Toronto. She is the Director of the Phase I Program, Clinical Lead for the Tumor Immunotherapy Program, and holds the BMO Chair in Precision Genomics. She is the PI of the institutional liquid biopsy program LIBERATE at the Princess Margaret. Dr. Siu has previously served on both the Board of Directors for ASCO and AACR.

Dana Farber Cancer Institute, Boston, MA, USA

Full Professor (University of Torino) and Director of the Laboratory of Molecular Oncology(Candiolo Cancer Institute-IRCCS, Candiolo, Italy). As a postdoc in the group of Bert Vogelstein (Johns Hopkins University), he performed the first comprehensive mutational profile of protein and lipid kinases in CRC. He focuses on precision oncology and pioneered the use of liquid biopsies to track cancer evolution during therapy.

Dana Farber Cancer Institute, Boston, MA, USA

Memorial Healthcare System, Pembroke Pines, USA

Medical Director Advanced Cancer Research Group Kirkland, Washington

Clínica del Country, Bogotá, Colombia

Stanford University, Stanford, CA, USA Dr. Max Diehn is the CRK Faculty Scholar and Associate Professor, Division Chief of Radiation and Cancer Biology, and Vice Chair of Research in the Department of Radiation Oncology at Stanford University. He is a physician scientist and practicing radiation oncologist whose main research focus is on the development and application of liquid biopsy technologies for cancer screening, treatment response assessment, and detection of minimal residual disease.

Dr. David Wishart is a Distinguished University Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta. He also holds adjunct appointments with the Faculty of Pharmaceutical Sciences and with the Department of Pathology and Laboratory Medicine. He has been with the University of Alberta since 1995. Dr. Wishart has been studying protein folding and misfolding for more than 30 years using a combination of computational and experimental approaches

Washington University School of Medicine, St. Louis, USA

Chris Abbosh is a principal clinical fellow in medical oncology at University College London, UK. He works on the Cancer Research UK funded lung TRACERx study, led by Professor Charles Swanton and funded by Cancer Research UK. Chris’s role within this study has been developing non-invasive biomarker strategies for lung cancer. His focus has been evaluating circulating tumor DNA (ctDNA) in terms of biology underpinning ctDNA release, use of ctDNA as a minimal residual disease biomarker

Dr. Amy Moore is the VP, Global Engagement and Patient Partnerships for LUNGevity Foundation. In that role, she seeks to build collaborations with stakeholders around the world to broaden clinical trials availability and access, to increase utilization of comprehensive biomarker testing and precision medicine and to understand regulatory and policy issues that impact delivery of optimal lung cancer care. As a trained virologist, she also serves as LUNGevity’s lead on all things related to COVID

Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA

University of Buenos Aires (UBA) - National Council for Scientific and Technical Research (CONICET), Argentina

Rajiv Gandhi Cancer Institute, Delhi, India

Dr Ola Khorshid is currently a Prof. of Medical Oncology, Malignant Hematology & BMT, Medical Oncology Department NCI, Cairo University She is the Chairman & Founder of Millennium HealthCare institution Chairman of Onco thoracic International Clinical Association OnTiC Cofounder of Orchid Oncology Center Secretary General of the Mediterranean Multidisciplinary Oncology Forum (MMOF) She received her master (1998) and PhD (2004) degrees in medical oncology and hematological malignancies from th

Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Chief Quality Officer for Cancer Services at the Mount Sinai Tisch Cancer Center. Her clinical focus is on lung cancer and palliative care. She is an RO1 funded clinical investigator whose work focuses on clinician-patient communication, evaluating treatment disparities and interventions focused on eliminating barriers to high quality cancer care delivery among racial and ethnic minorities.

ILSA, Foundation for the National Institutes of Health, USA